Triveni Bio's $115M haul ramps up push for precision I&I therapies

Triveni Bio has secured a $115 million series B financing round, setting the stage for it to move its lead antibody programme TRIV-509 into the clinic. The monoclonal antibody targeting kallikreins 5 and 7 is poised for an investigational new drug (IND) application in the first quarter of 2025.